Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial.

ABSTRACT:

Introduction

The migraine-preventive drug propranolol is efficacious in reducing pain from temporomandibular disorder, suggesting potential modifying or mediating effects of comorbid migraine.

Methods

In this randomized controlled trial, myofascial temporomandibular disorder patients were treated with propranolol or placebo for 9 weeks. The primary endpoint was change in a facial pain index derived from daily symptom diaries. Linear and logistic regression models tested for a migraine × treatment-group interaction in reducing facial pain index. Counterfactual models explored changes in headache impact and heart rate as mediators of propranolol's efficacy.

Results

Propranolol's efficacy in reducing facial pain index was greater among the 104 migraineurs than the 95 non

SUBMITTER: Tchivileva IE 

PROVIDER: S-EPMC8166404 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature